Impact of iron sucrose therapy on leucocyte surface molecules and reactive oxygen species in haemodialysis patients

Nephrology Dialysis Transplantation

Volumn 21, Issue 10, 2006, Pages 2834-2840

  Guz, Galip ^a,b   Glorieux, Griet L ^a   De Smet, Rita ^a   Waterloos, Marie Anne F ^a   Vanholder, Raymond C ^a   Dhondt, Annemieke W ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD11b; CD14; CD36; CD45; Iron sucrose; Reactive oxygen species

Indexed keywords

CD11B ANTIGEN; CD36 ANTIGEN; CD45 ANTIGEN; FERRIC HYDROXIDE SUCROSE; PHORBOL 13 ACETATE 12 MYRISTATE; PLACEBO; REACTIVE OXYGEN METABOLITE;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CELL STIMULATION; CHEMOLUMINESCENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; GRANULOCYTE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN CELL; IRON DEFICIENCY; IRON THERAPY; KIDNEY FAILURE; LEUKOCYTE; MALE; MONOCYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIGENS, CD11B; ANTIGENS, CD14; ANTIGENS, CD45; FEMALE; FERRIC COMPOUNDS; FLOW CYTOMETRY; GRANULOCYTES; HEMATINICS; HUMANS; KIDNEY FAILURE; LEUKOCYTES; LUMINESCENCE; MALE; MIDDLE AGED; MONOCYTES; REACTIVE OXYGEN SPECIES; RENAL DIALYSIS; RENAL INSUFFICIENCY;

EID: 33749609345     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl263     Document Type: Article

References (39)

1. Locatelli F, Aljama P et al. European Best Practice Guidelines Working Group. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004: 19: 1-47
2. Canziani MEF, Yumiya ST, Rangel EB, Manfredi SR, Neto MC, Draibe SA. Risk of bacterial infection in patients under intravenous iron therapy: dose vs length of treatment. Artif Organs 2001; 25: 866-869
3. Deichner R, Ziai F, Cohen G, Mullner M, Hoerl W. High-dose parenteral iron suucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003; 64: 728-736
4. Patruta SI, Edlinger R, Sunder-Plassmann G, Hoerl WH. Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency. J Am Soc Nephrol 1998; 9: 655-663
5. Tielemans CL, Lenclud CM, Wens R, Collart FE, Dratwa M. Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine. Nephrol Dial Transplant 1989; 4: 883-887
6. Drueke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217
7. Reis KA, Guz G, Ozdemir H et al. Intravenous iron therapy as a possible risk factor for atherosclerosis in end-stage renal disease. Int Heart J 2005; 46: 255-264
8. Febbraio M, Hajjar DP, Silverstein RL. CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest 2001; 108: 785-791
9. Harvath L, Balke JA, Christiansen NP, Russell AA, Skubitz KM. Selected antibodies to leukocyte common antigen (CD45) inhibit human neutrophil chemotaxis. J Immunol 1991; 146: 949-957
10. Jutila MA, Rott L, Berg EL, Butcher EC. Function and regulation of the neutrophil MEL-14 antigen in vivo: Comparison with LFA-1 and MAC-1. J Immunol 1989; 143: 3318-3324
11. Springer TA. Adhesion receptors of the immune system. Nature 1990; 346: 425-434
12. Bullen JJ. The significance of iron in infection. Rev Infect Dis 1981; 3: 1127-1138
13. Ward CG, Hammond J, Bullen J. Effect of iron compounds on antibacterial function of human polymorphs. Infect Immun 1986; 15: 723-730
14. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron saccharate administration. Nephrol Dial Transplant 2000; 15: 1827-1834
15. Roob JM, Khoschsorur G, Tiran A, Winklhofer-Roob BM. Vitamin E attenuates oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000; 11: 539-549
16. Scheiber-Mojdehkar B, Lutzky B, Schaufler R, Sturm B, Goldenberg H. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: No correlation to peroxide generation. J Am Soc Nephrol 2004; 15: 1648-1655
17. Sunder-Plassmann G, Hoerl WH. Safety of intravenous injection of iron saccharate in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1797-1802
18. Zanen AL, Adriaansen HJ, van Bommel EF, Posthuma R, de Jong GM Th. "Oversaturation" of transferrin after intravenous ferric gluconate (Ferrlecit®) in hemodialysis patients. Nephrol Dial Transplant 1996; 11: 820-824
19. Teehan GS, Bahdouch D, Ruthazer R, Balakrishnan VS, Snydman DR, Jaber BL. Iron storage indices: Novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. CID 2004; 38: 1090-1094
20. Feldman HI, Santanna J, Guo W et al. Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002; 13: 734-744
21. Brewster UC, Cocca SC, Reilly RF, Perazella MA. Effect of intravenous iron on hemodialysis catheter microbial colonization and blood-borne infection. Nephrology 2005; 10: 124-128
22. Hoen B, Paul-Dauphin A, Hestin D, Kessler M. Epibacdial: A multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients. J Am Soc Nephrol 1998; 9: 869-876
23. Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with the intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 2000; 11: 530-538
24. Hodkova M, Dusilova-Sulkova S, Skalicka A, Kalousova M, Zima T, Bartunkova J. Influence of parenteral iron therapy and oral vitamin E supplementation on neutrophil respiratory burst in chronic hemodialysis patients. Ren Fail 2005; 27: 135-141
25. Guo D, Jaber BL, Lee S et al. Impact of iron dextran on polymorphonuclear cell function among hemodialysis patients. Clin Nephrol 2002; 58: 134-142
26. Weiss G, Meusburger E, Radacher G, Garimorth K, Neyer U, Mayer G. Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003; 64: 572-578
27. Lim PS, Wei YH, Yu YL, Kho B. Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999; 14: 2680-2687
28. Michelis R, Gery R, Sela S et al. Carbonyl stress induced by intravenous iron during haemodialysis. Nephrol Dial Transplant 2003, 18: 924-930
29. Anraku M, Kitamura K, Shinohara A et al. Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 2004; 66: 841-848
30. Herrera J, Nava M, Romero F, Rodriguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. Am J Kidney Dis 2001; 37: 750-757
31. Muller C, Eisenbrand G, Gradinger M et al. Effects of hemodialysis, dialyser type and iron infusion on oxidative stress in uremic patients. Free Radic Res 2004; 38: 1093-1100
32. Guz G, Sahinaslan A, Dhondt AWC et al. Elevated cardiac troponin T in hemodialysis patients receiving more intravenous iron sucrose. Ren Fail 2004; 26: 663-672
33. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N. Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation. Am J Kidney Dis 2002; 40: 1005-4012
34. Cavdar C, Temiz A, Yenicerioglu Y et al. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients. Scand J Urol Nephrol 2003; 37: 77-82
35. Kalantar-Zadeh K, Regidor DL, McAllister CJ, Michael B, Warnock DG. Time-dependent associations between indices of iron store and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080
36. Hoepelman IM, Jaarsma EY, Verhoef J, Marx JJ. Polynuclear iron complexes impair the function of polymorphonuclear granulocytes. Br J Haematol 1988; 68: 385-389
37. Van Wyck DB. Labile iron: Manifestations and clinical implications. J Am Soc Nephrol 2004; 15: S107-S111
38. Chen WT, Lin YF, Yu FC, Kao WY, Huang WH, Yan HC. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: Influence of serum ferritin levels. Am J Kidney Dis 2003; 42: 158-166
39. Tepel M, Echelmeyer M, Orie NN, Zidek W. Increased intracellular reactive oxygen species in patients with end-stage renal failure: Effect of hemodialysis. Kidney Int 2000; 58: 867-872